NCT05371353

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Evaluating the Immune Persistence of Recombination Quadrivalent HPV Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomized Clinical Trial

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 600 (estimated)
• Sponsor: Shanghai Bovax Biotechnology Co., Ltd. · Industry
• Sex: Female
• Age: 9 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.

Conditions

• HPV Infections
• Cervical Cancer Stage IIa
• Vaginal Cancer
• Genital Wart
• CIN1
• CIN2
• CIN3

Timeline

• Start date: 2022-05-14
• Primary completion: 2027-05-01
• Completion: 2027-05-01
• First posted: 2022-05-12
• Last updated: 2024-04-17

Locations

2 sites across 1 country: China